Olokizumab

Drug Profile

Olokizumab

Alternative Names: Anti-IL6 - UCB; CDP-6038

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator UCB
  • Developer R-Pharm; UCB
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 06 Mar 2017 Phase-III clinical trials in Rheumatoid arthritis in Lithuania (EudraCT2015-005309-35)
  • 03 Mar 2017 Phase-III clinical trials in Rheumatoid arthritis (Combination therapy) in Latvia (SC) (EudraCT2015-005307-83)
  • 16 Dec 2016 R-Pharm re-initiates phase III trial in Rheumatoid arthritis (Combination therapy) in USA (SC) (NCT02760407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top